Tocilizmab (Actemra®)
Drug class: Interleukin-6 (IL-6) receptor antagonist; monoclonal antibody (1)
Mechanism of Action
Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors (sIL-6R and mIL-6R), thereby blocking IL-6 signaling. IL-6 is a pro-inflammatory cytokine produced by immune and other cells, including T cells, B cells, monocytes, and fibroblasts. By inhibiting IL-6 receptor-mediated signaling, tocilizumab reduces downstream inflammatory responses involved in immune-cell activation, acute-phase protein production, and hematopoietic processes. In inflammatory diseases such as rheumatoid arthritis, this action helps reduce IL-6-driven inflammation within affected joints (1).
Approved Indications
Rheumatoid arthritis (RA) (1)
Giant cell arteritis (GCA) (1)
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) (1)
Polyarticular juvenile idiopathic arthritis (PJIA) (1)
Systemic juvenile idiopathic arthritis (SJIA) (1)
Cytokine release syndrome (CRS) (1)
Coronavirus disease 2019 (COVID-19) (1)
Dosage and Administration
4–12 mg/kg every 2–4 weeks; SC: 162 mg once weekly to once every 2 weeks, depending on indication and patient factors (1)
Key clinical benefits
Reduces signs and symptoms of RA and improves physical function (2,3)
Inhibits radiographic progression and structural joint damage in RA (3)
Improves sustained remission and reduces glucocorticoid exposure in GCA (4)
Slows decline in pulmonary function in SSc-ILD (5)
Improves disease activity and reduces flares in PJIA and SJIA (6,7)
Provides rapid control of CAR T-cell-induced CRS (1)
Key clinical trials
OPTION - Tocilizumab in RA
In this phase 3 trial, investigators evaluated tocilizumab in 623 patients with moderate-to-severe active RA receiving background methotrexate. At Week 24, American College of Rheumatology 20% response (ACR20) was achieved by 59% with tocilizumab 8 mg/kg, 48% with 4 mg/kg, and 26% with placebo. The results demonstrated significant improvement in RA signs and symptoms with tocilizumab (2).
GiACTA - Tocilizumab in GCA
In this phase 3 trial, investigators enrolled 251 patients with GCA and compared tocilizumab 162 mg weekly or every other week with placebo, alongside prednisone tapering. At Week 52, sustained glucocorticoid-free remission was achieved in 56% and 53% of patients receiving weekly and every-2-week tocilizumab, respectively, versus 14% and 18% with placebo (P<0.001). Median cumulative prednisone exposure was also lower with tocilizumab (1,862 mg vs 3,296 mg and 3,818 mg with the 26- and 52-week placebo tapers) (4).
focuSSced - Tocilizumab in systemic sclerosis
In this phase 3 trial, investigators randomized 210 patients with early diffuse systemic sclerosis to tocilizumab 162 mg SC weekly or placebo for 48 weeks. At Week 48, tocilizumab was associated with better preservation of FVC% predicted than placebo (LSM difference 4.2 percentage points; 95% CI, 2.0–6.4; P=0.0002). Among patients with SSc-ILD, FVC% predicted changed by −0.1% with tocilizumab vs −6.3% with placebo, supporting its role in slowing pulmonary function decline (5).
CHERISH - Tocilizumab in PJIA
In this phase 3, randomized, double-blind withdrawal trial, 188 patients with PJIA received open-label tocilizumab for 16 weeks, after which responders were randomized to continue tocilizumab or switch to placebo for 24 weeks. JIA flare occurred in 25.6% of patients continuing tocilizumab versus 48.1% with placebo (P=0.0024), demonstrating sustained control of disease activity with tocilizumab (6).
TENDER - Tocilizumab in SJIA
In this Phase 3, randomized, double-blind, placebo-controlled trial, 112 children with SJIA received intravenous tocilizumab every 2 weeks or placebo for 12 weeks. At Week 12, 85% of patients receiving tocilizumab achieved ≥30% improvement in JIA symptoms with resolution of fever versus 24% with placebo (P<0.001). At Week 52, 80% achieved ≥70% improvement with no fever, including 59% who achieved ≥90% improvement (7).
Common Adverse Events
Upper respiratory tract infections (1)
Headache (1)
Hypertension (1)
Increased alanine aminotransferase levels (1)
Injection-site reactions with SC administration (1)
Infusion-related reactions with IV administration (1)
Contraindications / Precautions
Serious hypersensitivity to tocilizumab or its components (1)
Increased risk of serious infections, including TB and opportunistic infections (1)
Avoid initiation in patients with significant neutropenia, thrombocytopenia, or elevated liver enzymes (1)
Monitor for hepatotoxicity, neutropenia, and thrombocytopenia (1)
May cause gastrointestinal perforation, particularly in patients with diverticulitis or concomitant corticosteroid/NSAID use (1)
Live vaccines should not be administered during treatment (1)
Special Notes for Clinician
Screen for latent TB before initiating treatment, except when treating COVID-19 (1)
Monitor complete blood count and liver function tests during treatment (1)
Interrupt treatment if a serious infection develops until the infection is controlled (1)
Monitor lipid parameters approximately 4–8 weeks after treatment initiation (1)
Avoid initiation if absolute neutrophil count (ANC) is <2,000/mm³ or platelet count is <100,000/mm³ for most indications (1)
Monitor for signs of gastrointestinal perforation, particularly in patients with diverticular disease (1)
Abbreviations
ACR: American College of Rheumatology; ANC: absolute neutrophil count; CAR: chimeric antigen receptor; COVID-19: coronavirus disease 2019; CRS: cytokine release syndrome; DMARDs: disease-modifying antirheumatic drugs; FVC: forced vital capacity; GCA: giant cell arteritis; IL-6: interleukin-6; IV: intravenous; PJIA: polyarticular juvenile idiopathic arthritis; q1w: every week; q2w: every 2 weeks; q4w: every 4 weeks; RA: rheumatoid arthritis; SC: subcutaneous; SSc-ILD: systemic sclerosis-associated interstitial lung disease; SJIA: systemic juvenile idiopathic arthritis; TB: tuberculosis.
References
U.S. Food and Drug Administration. ACTEMRA® (tocilizumab) Prescribing Information. Revised August 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125472s059lbl.pdf?utm_source=chatgpt.com Accessed on: 08 Oct 2026.
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study). Lancet. 2008;371:987–997.
Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. Ann Rheum Dis. 2014;73:1477–1486.
Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317–328.
Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8:963–974.
Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis. Ann Rheum Dis. 2015;74:1110–1117.
De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395.
About the Author
Dr. Sheeba Rani is a Pharm.D graduate currently working as a medical writer, with growing expertise in medical data annotation. Passionate about clinical research and medical writing, she has a keen interest in exploring novel pharmacotherapeutic agents and leveraging data annotation techniques to advance patient care and healthcare innovation. Beyond her professional pursuits, Dr. Sheeba enjoys cooking and spending time outdoors, finding balance between science, creativity, and wellness.
Disclaimer
The content published on this platform has been developed by independent medical writers from diverse healthcare backgrounds, including members of the MedWriters Alumni Network. While every effort has been made to ensure accuracy, the authors, Rxnews team, partners, agents, and sponsors accept no responsibility for errors, omissions, or inaccuracies in this article, whether due to negligence or otherwise, nor for any consequences arising from its use. Inclusion or exclusion of any product does not imply endorsement or rejection by the publisher. For complaints or feedback, please write to contact@rxnews.in
Comments